New Study Finds 85% of Aneurysms Identified by Viz™ ANEURYSM had not Been Referred for Neurovascular Review

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today shared highlights of new data being presented at the Society of Vascular and Interventional Neuroradiology (SVIN) in Los Angeles next week, demonstrating the significant impact of Viz ANEURYSM at a large hospital system.

After screening nearly 1,200 computed tomography angiograms (CTAs) for stroke evaluation across eight stroke centers across Texas with Viz ANEURYSM, a total of 85% of the aneurysms detected by Viz ANEURYSM had not been previously referred for follow-up. The median size of all aneurysms was 5 mm, and almost half (45%) were larger than 7 mm.

“In our study, Viz ANEURYSM not only demonstrated the value of automated detection but also the significant importance of facilitating referrals to the appropriate specialist, so fewer aneurysms get missed, helping more people,” Sunil A. Sheth, MD, primary investigator for the study, a vascular and interventional neurologist, and Assistant Professor of Neurology at UTHealth McGovern Medical School.

Viz ANEURYSM automatically analyzes CTAs for suspected cerebral aneurysm and facilitates referrals, thus enabling hospital systems to ensure that healthcare providers can diagnose patients and receive the care they need at the right time.  This new real world data demonstrates the impact that automatic detection and Viz’s AI-powered care coordination can bring to patients with suspected unruptured cerebral aneurysms.

“This real-world clinical evidence validates the impact of Viz ANEURYSM in a large study. These data demonstrate the importance of workflow efficiency that Viz can bring to unruptured cerebral aneurysm, assuring the patient is referred to the right provider, possibly impacting rupture and mortality rates,” said Jayme Strauss, chief clinical officer of Viz.ai.

For more information on the study results and Viz ANEURYSM, please join a webinar on Tuesday, November 29th at 6pm ET. Register here.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.